News

Mannin and Cyclica Enter JV to Rapidly Develop COVID-19 Drugs

Mannin-Cyclica JV to rapidly develop drugs to treat COVID-19 patients using the Tie2 receptor expertise of Mannin and Cyclica’s AI-augmented drug discovery platform The projects will include small molecule treatments to treat infectious diseases including COVID-19 and influenza Toronto, Canada and Leipzig, Germany, April 20th, 2020 – Mannin Research has entered a joint venture (JV) between Mannin GmbH, a German Mannin subsidiary, and Cyclica Inc. The Mannin – Cyclica...

Mannin Research Inc. Presents Data Showing Potential Treatment to Protect Kidney in Acute Kidney Injury Using Mannin Tie2 Activator

Data presented during “Acute Kidney Injury” symposium at the American Society for Nephrology 2019 Annual Meeting Toronto, Canada December 2,2019 Mannin Research Inc.’s (Mannin) Chief Scientific Officer, Dr. Susan Quaggin, presented positive data on a potential new treatment for acute kidney injury (AKI), during the annual Kidney Week meeting, in Washington DC in November 2019. The data suggests that the Angiopoietin-Tie2 signaling pathway is a promising therapeutic target to prevent...

Mannin announces $10.1M grant, part of $15.65M investment to develop new therapeutics for glaucoma

Senior Leadership team to expand with Isabel Antholz joining as Managing Director Toronto, Canada and Leipzig, Germany, November 27,2019 Mannin Research Inc. (Mannin), is pleased to announce that its wholly owned subsidiary, Mannin GmbH, has received a substantial €6.9M ($10.1M CAD) grant, from the Free State of Saxony, in Germany. This grant is a contribution to a multi-year €10.7M ($15.65M CAD) investment by Mannin into its German research and...